According to Future Market Insights research, during the projected period, the global prostate-specific antigen (PSA) testing market is expected to grow at a CAGR of 12.0%. The market value is projected to increase from US$ 6.3 Billion in 2023 to US$ 19.5 billion by 2033. The global prostate-specific antigen (PSA) testing market was valued at US$ 5.7 billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 11.1% in 2023.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 5.7 Billion |
| Market Value 2023 | US$ 6.3 Billion |
| Market Value 2033 | US$ 19.5 Billion |
| CAGR 2023 to 2033 | 12.0% |
| Share of Top 5 Countries | 60.1% |
| Key Players | The key players in the Prostate-Specific Antigen (PSA) Testing Market Are Xiamen Biotime Biotechnology Co.; Ltd.; HWTAi; OptiBio Co.; Ltd; Jiangsu MicroDiag Biomedicine Technology Co.; Ltd.; Beijing Hotgen Biotechn Co.; Ltd; Humasis; Accuquik™ Test Kits; CTK Biotech; Inc; INTEC; XIAMEN BOSON BIOTECH CO.; LTD; AccuBioTech Co.; Ltd.; Bio-Rad Laboratories; Inc.; Accuquik Test Kits; OPKO Health; Inc.; bioMérieux SA; Beckman Coulter; Inc.; Abbott; Siemens Healthcare; DiaSorin ; Roche; Mediwatch (LABORIE); BodiTech; Bristol-Myers Squibb Company; GE Healthcare; Endocare ; GlaxoSmithKline; Anixa Biosciences; Ortho Clinical ; Fujirebio; Pharmacia Delfia |
A crucial tumor marker for prostate cancer, prostate specific antigen (PSA), is a type of protein that is only released by certain cells. Although it is not a chemical specific to the prostate, its increased presence in blood serum is used to identify males with prostate cancer. A digital rectal exam (DRE) and PSA tests are used to check for prostate cancer in asymptomatic men. Clinicians and healthcare professionals now, frequently use PSA screening to look for potential prostate cancer cases to help them understand the nature of the issue.
Both healthy and cancerous cells of the prostate gland generate the PSA protein, which is exclusive to the prostate. A blood sample is sent to a lab for analysis as part of the PSA test, which gauges the level of PSA in the body. PSA levels in blood are often measured in nanograms (ng/mL).
Some organizations do advise starting PSA testing at age 40 or 45 for men who have a higher chance of developing prostate cancer. Males of color, those with BRCA2 germline variations (and, to a lesser extent, BRCA1 variants), and males whose father or brother had prostate cancer are among those at risk.
Overall, the increasing adoption of latest technologies and new product launches such as Compared to the presently utilized prostate-specific antigen (PSA) blood test, the prostate screening EpiSwitch (PSE) blood test is more than 90 percent accurate. this factors will boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the prostate-specific antigen (PSA) testing market grew at a CAGR of 9.9% between 2018 and 2022. Prostate-specific antigen (PSA) testing market contributes 3.4% revenue share to the cancer diagnostics market valued at US$ 166.2 Billion in 2022.
In order to monitor the progression of prostate cancer in men who had already received a diagnosis, the FDA originally authorized the PSA test in 1986. Patients with prostate cancer usually have increased PSA levels in their blood. In year 1994, the FDA approved the combination of PSA test with DRE to aid in the diagnosis of prostate cancer.
As more information about the advantages and disadvantages of prostate cancer screening became available starting about 2008, a number of professional medical organizations started to issue warnings against the PSA test's widespread use in population screening. The majority of organizations advise those who are thinking about PSA screening to first go over the advantages and disadvantages with their doctors.
Prostate explicit antigen testing market is driving ahead a result of expansion in geriatric population. Additionally, the growth of the prostate specific antigen market is influenced by technological advancements in prostate cancer testing and treatment, as well as a number of reimbursement policies for prostate cancer treatment in both developed and developing countries.
Creating awareness about diseases is an essential aspect of early detection and screening. If the public has a general understanding of diseases and symptoms, action plans can be better implemented. On the other hand, if there is a lack of awareness, it stops people from taking preventive measures or availing treatments.
Considering this, FMI expects the prostate-specific antigen (PSA) testing market to grow at a CAGR of 12.0% through the forecasted years.
The rising prevalence of prostate cancer in men, particularly among those over 50, is driving the global market for prostate-specific specific antigen testing. After treatment for prostate cancer, PSA levels must also be checked on a regular basis.
New item dispatches and new technological advancements are open doors for development in the market.
A few reimbursement strategies in different created and creating locales cover yearly public service announcement testing among men with age at least 50. Besides, public service announcement testing being incorporated as a piece of the yearly wellbeing inclusion in created countries like USA is supposed to set out promising open doors for market players. These factors are expected to provide growth opportunities to key players in the market over the forecast period.
Principal Consultant
Prostate explicit antigen testing market need to confront a few difficult circumstances due to the misleading positive or bogus adverse consequences of public service announcement test. Additionally, activities like public service announcement screening had a great deal of secondary effects, for example, troubles in progression of pee, consequences for working of entrails, erectile brokenness and successive torments alongside bogus outcomes; subsequently blocking the development of prostate explicit antigen testing market.
Higher improvement in the innovation resulting in most streamlined and exact outcomes in the tests like prostate wellbeing file (phi) can lessen the development in public service announcement testing market except if there is an adjustment of how the tests are dealt with.
Over determination of clinically immaterial prostate malignant growth, combined with exaggeration of the outcomes is a significant hindrance in the reception of public service announcement testing.
These factors are expected to hamper revenue growth of the prostate-specific antigen (PSA) testing market over the forecast period.
In United States, prostate cancer is the most common malignancy among men, except from skin cancer.
During the projected period, the market for prostate-specific antigen (PSA) testing in the United States is anticipated to grow at a CAGR of 10.2%.
Due to the high prevalence of prostate cancer diagnostic methods will be in demand for prostate-specific antigen testing, which will drive the expansion of the market.
Germany dominated the European market for prostate-specific antigen (PSA) testing market and accounted for around 29.8% of the market share in 2022.
Recent investigations by University of East Anglia’, Europe, have shown that the prostate screening blood test EpiSwitch (PSE) is more accurate than the currently used PSA blood test by more than 90%. The new test provides an accurate and speedy cancer screening diagnosis, according to the study team. The PSE test offers a rapid, minimally invasive prostate cancer detection and has exceptional effectiveness when used to screen a population at risk.
Over the years, due to growing number of research activities to develop new testing options in prostate cancer testing, Germany market for PSA testing will grow.
The safe and successful use PSA testing in Germany will influence other European countries to also opt for this method, ultimately expanding the overall market.
China is projected to be the most attractive market in the East Asia prostate-specific antigen (PSA) testing market and is expected to grow over a significant CAGR of 11.2%.
The growing public and professional awareness of the condition is one of the main factors influencing the growth of the prostate-specific antigen (PSA) testing market in China.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Immunoassay segment held the major chunk of about 56.8% in global market by the end of 2022.
Many of infectious diseases require rapid diagnosis that’s where prostate-specific antigen (PSA) testing market diagnostics plays a significant role.
Prostate-specific antigen (PSA) testing involves testing type such as immunoassays, ELISA kits, lateral flow assays, chemiluminescent immunoassays (CLIAs), radioimmunoassay, point-of-care testing kits, cassette/cards, strips. However, Immunoassay testing is preferred over POCT because immunoassays have more specificity and more reliable results.
Overall, PSA test is used for detection of prostate-specific antigen due to their high specificity.
Whole blood segment accounted for revenue share of 52.4% in the global market at the end of 2022.
Complete blood count tests are frequently advised by doctors to track patient’s health. This blood test can be used in cancer therapy to aid in the diagnosis of a malignancy or to track how the disease or its treatment is impacting the patient's body.
Overall, whole blood offers a convenient sample type for prostate-specific antigen (PSA) testing market treating products, making it the most significant sample for this segment.
Hospitals segment accounted for revenue share of 44.1% in the global market at the end of 2022.
Hospitals have availability of testing kits and hospitals are main source of blood sample withdrawing channel for prostate-specific antigen (PSA) testing.
Overall, hospitals offers a convenient testing options for prostate-specific antigen (PSA) testing, making it the dominant end user for this segment.
The prostate-specific antigen (PSA) testing market's major companies are concentrating on diversifying their product offerings to boost their market share and establish a presence in developing nations. Pricing strategies, market strategies, technology improvements, regulatory compliance, and acquisition and distribution agreements with other firms to extend their company are the main tactics used by manufacturers to acquire a competitive advantage in the market.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the Prostate-specific Antigen (PSA) Testing market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, Nordics, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, North Africa and GCC Countries |
| Key Segments Covered | Test Type, Sample Type, End User, Region |
| Key Companies Profiled | Xiamen Biotime Biotechnology Co., Ltd.; HWTAi; OptiBio Co., Ltd; Jiangsu MicroDiag Biomedicine Technology Co., Ltd.; Beijing Hotgen Biotechn Co., Ltd; Humasis, Accuquik™ Test Kits; CTK Biotech, Inc.; INTEC; XIAMEN BOSON BIOTECH CO., LTD; AccuBioTech Co., Ltd.; Bio-Rad Laboratories, Inc.; Accuquik Test Kits; OPKO Health, Inc.; bioMérieux SA; Beckman Coulter, Inc.; Abbott; Siemens Healthcare; DiaSorin; F. Hoffmann-La Roche Ltd; Mediwatch (LABORIE); BodiTech; Bristol-Myers Squibb Company; GE Healthcare; Endocare; GlaxoSmithKline; Anixa Biosciences; Ortho Clinical; Fujirebio; Pharmacia Delfia |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Aging populations and prostate cancer awareness influencing the market growth.
Asia Pacific is expanding quickly because of better healthcare infrastructure.
Laboratory-based PSA testing segment occupies a dominant position in the market.
The rising incidence of prostate cancer and improvements in diagnostic technology.
The North America has seen significant adoption of PSA testing on a global scale.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development/Innovation Trends
4. Key Success Factors
4.1. Product Adoption Analysis
4.2. Regulatory Scenario
4.3. Reimbursement Landscape
4.4. PESTLE Analysis
4.5. Porter’s Analysis
4.6. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.1.3. Global IVD Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Increasing Treatment Seeking Rate
5.2.3. New Test Type Launches/Approvals
5.2.4. Increasing Incidence of Prostate Cancer
5.2.5. Government Initiatives to Combat Prostate Cancer
5.2.6. Companies Increasingly Spending on R&D and Focus on Innovation
5.2.7. Collaborations and Agreements between Manufacturers
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis - Impact Assessment
6.1. COVID-19 and Impact Analysis
6.1.1. By Test Type
6.1.2. By Sample Type
6.1.3. By End User
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) By Test Type, 2018 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033
8.3.1. Immunoassays
8.3.1.1. ELISA kits
8.3.1.2. Lateral flow assays
8.3.1.3. Chemiluminescent immunoassays (CLIAs)
8.3.1.4. Radioimmunoassay
8.3.2. Kits
8.3.2.1. Cassette/Cards
8.3.2.2. Strips
8.4. Market Attractiveness Analysis by Test Type
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sample Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis by Sample Type, 2018 to 2022
9.3. Current and Future Market Size (US$ Million) and Forecast by Sample Type, 2023 to 2033
9.3.1. Whole Blood
9.3.2. Serum
9.3.3. Plasma
9.4. Market Attractiveness Analysis by Sample Type
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) By End User, 2018 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033
10.3.1. Hospitals
10.3.2. Diagnostics laboratories
10.3.3. Specialty Clinics
10.3.4. Research Institutes
10.3.5. Others
10.4. Market Attractiveness Analysis by End User
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Trend Analysis by Region, 2018 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. South Asia
11.3.5. East Asia
11.3.6. Oceania
11.3.7. Middle East & Africa
11.4. Market Attractiveness Analysis By Country
12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. USA
12.3.1.2. Canada
12.3.2. By Test Type
12.3.3. By Sample Type
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Test Type
12.4.3. By Sample Type
12.4.4. By End User
12.5. Market Trends
12.6. Key Market Participant - Intensity Mapping
12.7. Drivers & Restraints Impact Analysis
12.8. Country-wise Analysis
12.8.1. USA Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Test Type
12.8.1.2.2. By Sample Type
12.8.1.2.3. By End User
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Test Type
12.8.2.2.2. By Sample Type
12.8.2.2.3. By End User
13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Test Type
13.3.3. By Sample Type
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Test Type
13.4.3. By Sample Type
13.4.4. By End User
13.5. Market Trends
13.6. Key Market Participant - Intensity Mapping
13.7. Drivers & Restraints Impact Analysis
13.8. Country-wise Analysis
13.8.1. Brazil Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Test Type
13.8.1.2.2. By Sample Type
13.8.1.2.3. By End User
13.8.2. Mexico Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Test Type
13.8.2.2.2. By Sample Type
13.8.2.2.3. By End User
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Test Type
13.8.3.2.2. By Sample Type
13.8.3.2.3. By End User
14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. UK
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Test Type
14.3.3. By Sample Type
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Test Type
14.4.3. By Sample Type
14.4.4. By End User
14.5. Market Trends
14.6. Key Market Participant - Intensity Mapping
14.7. Drivers & Restraints Impact Analysis
14.8. Country-wise Analysis
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Test Type
14.8.1.2.2. By Sample Type
14.8.1.2.3. By End User
14.8.2. Italy Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Test Type
14.8.2.2.2. By Sample Type
14.8.2.2.3. By End User
14.8.3. France Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Test Type
14.8.3.2.2. By Sample Type
14.8.3.2.3. By End User
14.8.4. UK Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Test Type
14.8.4.2.2. By Sample Type
14.8.4.2.3. By End User
14.8.5. Spain Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Test Type
14.8.5.2.2. By Sample Type
14.8.5.2.3. By End User
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Test Type
14.8.6.2.2. By Sample Type
14.8.6.2.3. By End User
14.8.7. Russia Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Test Type
14.8.7.2.2. By Sample Type
14.8.7.2.3. By End User
15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Malaysia
15.3.1.4. Thailand
15.3.1.5. Rest of South Asia
15.3.2. By Test Type
15.3.3. By Sample Type
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Test Type
15.4.3. By Sample Type
15.4.4. By End User
15.5. Market Trends
15.6. Key Market Participant - Intensity Mapping
15.7. Drivers & Restraints Impact Analysis
15.8. Country-wise Analysis
15.8.1. India Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Test Type
15.8.1.2.2. By Sample Type
15.8.1.2.3. By End User
15.8.2. Indonesia Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Test Type
15.8.2.2.2. By Sample Type
15.8.2.2.3. By End User
15.8.3. Malaysia Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Test Type
15.8.3.2.2. By Sample Type
15.8.3.2.3. By End User
15.8.4. Thailand Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Test Type
15.8.4.2.2. By Sample Type
15.8.4.2.3. By End User
16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Test Type
16.3.3. By Sample Type
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Test Type
16.4.3. By Sample Type
16.4.4. By End User
16.5. Market Trends
16.6. Key Market Participant - Intensity Mapping
16.7. Drivers & Restraints Impact Analysis
16.8. Country-wise Analysis
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Test Type
16.8.1.2.2. By Sample Type
16.8.1.2.3. By End User
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Test Type
16.8.2.2.2. By Sample Type
16.8.2.2.3. By End User
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Test Type
16.8.3.2.2. By Sample Type
16.8.3.2.3. By End User
17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Test Type
17.3.3. By Sample Type
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Test Type
17.4.3. By Sample Type
17.4.4. By End User
17.5. Market Trends
17.6. Key Market Participant - Intensity Mapping
17.7. Drivers & Restraints Impact Analysis
17.8. Country-wise Analysis
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Test Type
17.8.1.2.2. By Sample Type
17.8.1.2.3. By End User
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Test Type
17.8.2.2.2. By Sample Type
17.8.2.2.3. By End User
18. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. GCC Country
18.3.1.2. Turkey
18.3.1.3. South Africa
18.3.1.4. North Africa
18.3.1.5. Rest of MEA
18.3.2. By Test Type
18.3.3. By Sample Type
18.3.4. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Test Type
18.4.3. By Sample Type
18.4.4. By End User
18.5. Market Trends
18.6. Key Market Participant - Intensity Mapping
18.7. Drivers & Restraints Impact Analysis
18.8. Country-wise Analysis
18.8.1. GCC Country Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Test Type
18.8.1.2.2. By Sample Type
18.8.1.2.3. By End User
18.8.2. Türkiye Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Test Type
18.8.2.2.2. By Sample Type
18.8.2.2.3. By End User
18.8.3. South Africa Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Test Type
18.8.3.2.2. By Sample Type
18.8.3.2.3. By End User
18.8.4. North South Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Test Type
18.8.4.2.2. By Sample Type
18.8.4.2.3. By End User
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players (%)
19.3. Market Concentration
19.4. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Key Development Analysis
20.3. Branding and Promotional Strategies, By Key Players
20.4. Competition Deep Dive
20.4.1. Xiamen Biotime Biotechnology Co. Ltd.
20.4.1.1. Overview
20.4.1.2. Product Portfolio
20.4.1.3. Key Financials
20.4.1.4. SWOT Analysis
20.4.1.5. Key Developments
20.4.1.6. Sales Footprint
20.4.1.7. Strategy Overview
20.4.1.7.1. Marketing Strategy
20.4.1.7.2. Product Strategy
20.4.1.7.3. Channel Strategy
20.4.2. HWTAi,
20.4.2.1. Overview
20.4.2.2. Product Portfolio
20.4.2.3. Key Financials
20.4.2.4. SWOT Analysis
20.4.2.5. Key Developments
20.4.2.6. Sales Footprint
20.4.2.7. Strategy Overview
20.4.2.7.1. Marketing Strategy
20.4.2.7.2. Product Strategy
20.4.2.7.3. Channel Strategy
20.4.3. OptiBio Co., Ltd
20.4.3.1. Overview
20.4.3.2. Product Portfolio
20.4.3.3. Key Financials
20.4.3.4. SWOT Analysis
20.4.3.5. Key Developments
20.4.3.6. Sales Footprint
20.4.3.7. Strategy Overview
20.4.3.7.1. Marketing Strategy
20.4.3.7.2. Product Strategy
20.4.3.7.3. Channel Strategy
20.4.4. Jiangsu MicroDiag Biomedicine Technology Co., Ltd.
20.4.4.1. Overview
20.4.4.2. Product Portfolio
20.4.4.3. Key Financials
20.4.4.4. SWOT Analysis
20.4.4.5. Key Developments
20.4.4.6. Sales Footprint
20.4.4.7. Strategy Overview
20.4.4.7.1. Marketing Strategy
20.4.4.7.2. Product Strategy
20.4.4.7.3. Channel Strategy
20.4.5. Beijing Hotgen Biotechn Co., Ltd
20.4.5.1. Overview
20.4.5.2. Product Portfolio
20.4.5.3. Key Financials
20.4.5.4. SWOT Analysis
20.4.5.5. Key Developments
20.4.5.6. Sales Footprint
20.4.5.7. Strategy Overview
20.4.5.7.1. Marketing Strategy
20.4.5.7.2. Product Strategy
20.4.5.7.3. Channel Strategy
20.4.6. Humasis, Accuquik™ Test Kits
20.4.6.1. Overview
20.4.6.2. Product Portfolio
20.4.6.3. Key Financials
20.4.6.4. SWOT Analysis
20.4.6.5. Key Developments
20.4.6.6. Sales Footprint
20.4.6.7. Strategy Overview
20.4.6.7.1. Marketing Strategy
20.4.6.7.2. Product Strategy
20.4.6.7.3. Channel Strategy
20.4.7. CTK Biotech, Inc
20.4.7.1. Overview
20.4.7.2. Product Portfolio
20.4.7.3. Key Financials
20.4.7.4. SWOT Analysis
20.4.7.5. Key Developments
20.4.7.6. Sales Footprint
20.4.7.7. Strategy Overview
20.4.7.7.1. Marketing Strategy
20.4.7.7.2. Product Strategy
20.4.7.7.3. Channel Strategy
20.4.8. INTEC
20.4.8.1. Overview
20.4.8.2. Product Portfolio
20.4.8.3. Key Financials
20.4.8.4. SWOT Analysis
20.4.8.5. Key Developments
20.4.8.6. Sales Footprint
20.4.8.7. Strategy Overview
20.4.8.7.1. Marketing Strategy
20.4.8.7.2. Product Strategy
20.4.8.7.3. Channel Strategy
20.4.9. XIAMEN BOSON BIOTECH CO., LTD
20.4.9.1. Overview
20.4.9.2. Product Portfolio
20.4.9.3. Key Financials
20.4.9.4. SWOT Analysis
20.4.9.5. Key Developments
20.4.9.6. Sales Footprint
20.4.9.7. Strategy Overview
20.4.9.7.1. Marketing Strategy
20.4.9.7.2. Product Strategy
20.4.9.7.3. Channel Strategy
20.4.10. AccuBioTech Co., Ltd.
20.4.10.1. Overview
20.4.10.2. Product Portfolio
20.4.10.3. Key Financials
20.4.10.4. SWOT Analysis
20.4.10.5. Key Developments
20.4.10.6. Sales Footprint
20.4.10.7. Strategy Overview
20.4.10.7.1. Marketing Strategy
20.4.10.7.2. Product Strategy
20.4.10.7.3. Channel Strategy
20.4.11. Bio-Rad Laboratories, Inc.
20.4.11.1. Overview
20.4.11.2. Product Portfolio
20.4.11.3. Key Financials
20.4.11.4. SWOT Analysis
20.4.11.5. Key Developments
20.4.11.6. Sales Footprint
20.4.11.7. Strategy Overview
20.4.11.7.1. Marketing Strategy
20.4.11.7.2. Product Strategy
20.4.11.7.3. Channel Strategy
20.4.12. Accuquik Test Kits
20.4.12.1. Overview
20.4.12.2. Product Portfolio
20.4.12.3. Key Financials
20.4.12.4. SWOT Analysis
20.4.12.5. Key Developments
20.4.12.6. Sales Footprint
20.4.12.7. Strategy Overview
20.4.12.7.1. Marketing Strategy
20.4.12.7.2. Product Strategy
20.4.12.7.3. Channel Strategy
20.4.13. OPKO Health, Inc.
20.4.13.1. Overview
20.4.13.2. Product Portfolio
20.4.13.3. Key Financials
20.4.13.4. SWOT Analysis
20.4.13.5. Key Developments
20.4.13.6. Sales Footprint
20.4.13.7. Strategy Overview
20.4.13.7.1. Marketing Strategy
20.4.13.7.2. Product Strategy
20.4.13.7.3. Channel Strategy
20.4.14. bioMérieux SA
20.4.14.1. Overview
20.4.14.2. Product Portfolio
20.4.14.3. Key Financials
20.4.14.4. SWOT Analysis
20.4.14.5. Key Developments
20.4.14.6. Sales Footprint
20.4.14.7. Strategy Overview
20.4.14.7.1. Marketing Strategy
20.4.14.7.2. Product Strategy
20.4.14.7.3. Channel Strategy
20.4.15. Beckman Coulter, Inc
20.4.15.1. Overview
20.4.15.2. Product Portfolio
20.4.15.3. Key Financials
20.4.15.4. SWOT Analysis
20.4.15.5. Key Developments
20.4.15.6. Sales Footprint
20.4.15.7. Strategy Overview
20.4.15.7.1. Marketing Strategy
20.4.15.7.2. Product Strategy
20.4.15.7.3. Channel Strategy
20.4.16. Abbott
20.4.16.1. Overview
20.4.16.2. Product Portfolio
20.4.16.3. Key Financials
20.4.16.4. SWOT Analysis
20.4.16.5. Key Developments
20.4.16.6. Sales Footprint
20.4.16.7. Strategy Overview
20.4.16.7.1. Marketing Strategy
20.4.16.7.2. Product Strategy
20.4.16.7.3. Channel Strategy
20.4.17. Siemens Healthcare
20.4.17.1. Overview
20.4.17.2. Product Portfolio
20.4.17.3. Key Financials
20.4.17.4. SWOT Analysis
20.4.17.5. Key Developments
20.4.17.6. Sales Footprint
20.4.17.7. Strategy Overview
20.4.17.7.1. Marketing Strategy
20.4.17.7.2. Product Strategy
20.4.17.7.3. Channel Strategy
20.4.18. DiaSorin
20.4.18.1. Overview
20.4.18.2. Product Portfolio
20.4.18.3. Key Financials
20.4.18.4. SWOT Analysis
20.4.18.5. Key Developments
20.4.18.6. Sales Footprint
20.4.18.7. Strategy Overview
20.4.18.7.1. Marketing Strategy
20.4.18.7.2. Product Strategy
20.4.18.7.3. Channel Strategy
20.4.19. F. Hoffmann-La Roche Ltd
20.4.19.1. Overview
20.4.19.2. Product Portfolio
20.4.19.3. Key Financials
20.4.19.4. SWOT Analysis
20.4.19.5. Key Developments
20.4.19.6. Sales Footprint
20.4.19.7. Strategy Overview
20.4.19.7.1. Marketing Strategy
20.4.19.7.2. Product Strategy
20.4.19.7.3. Channel Strategy
20.4.20. Mediwatch (LABORIE)
20.4.20.1. Overview
20.4.20.2. Product Portfolio
20.4.20.3. Key Financials
20.4.20.4. SWOT Analysis
20.4.20.5. Key Developments
20.4.20.6. Sales Footprint
20.4.20.7. Strategy Overview
20.4.20.7.1. Marketing Strategy
20.4.20.7.2. Product Strategy
20.4.20.7.3. Channel Strategy
20.4.21. BodiTech
20.4.21.1. Overview
20.4.21.2. Product Portfolio
20.4.21.3. Key Financials
20.4.21.4. SWOT Analysis
20.4.21.5. Key Developments
20.4.21.6. Sales Footprint
20.4.21.7. Strategy Overview
20.4.21.7.1. Marketing Strategy
20.4.21.7.2. Product Strategy
20.4.21.7.3. Channel Strategy
20.4.22. Bristol-Myers Squibb Company
20.4.22.1. Overview
20.4.22.2. Product Portfolio
20.4.22.3. Key Financials
20.4.22.4. SWOT Analysis
20.4.22.5. Key Developments
20.4.22.6. Sales Footprint
20.4.22.7. Strategy Overview
20.4.22.7.1. Marketing Strategy
20.4.22.7.2. Product Strategy
20.4.22.7.3. Channel Strategy
20.4.23. GE Healthcare
20.4.23.1. Overview
20.4.23.2. Product Portfolio
20.4.23.3. Key Financials
20.4.23.4. SWOT Analysis
20.4.23.5. Key Developments
20.4.23.6. Sales Footprint
20.4.23.7. Strategy Overview
20.4.23.7.1. Marketing Strategy
20.4.23.7.2. Product Strategy
20.4.23.7.3. Channel Strategy
20.4.24. Endocare
20.4.24.1. Overview
20.4.24.2. Product Portfolio
20.4.24.3. Key Financials
20.4.24.4. SWOT Analysis
20.4.24.5. Key Developments
20.4.24.6. Sales Footprint
20.4.24.7. Strategy Overview
20.4.24.7.1. Marketing Strategy
20.4.24.7.2. Product Strategy
20.4.24.7.3. Channel Strategy
20.4.25. GlaxoSmithKline
20.4.25.1. Overview
20.4.25.2. Product Portfolio
20.4.25.3. Key Financials
20.4.25.4. SWOT Analysis
20.4.25.5. Key Developments
20.4.25.6. Sales Footprint
20.4.25.7. Strategy Overview
20.4.25.7.1. Marketing Strategy
20.4.25.7.2. Product Strategy
20.4.25.7.3. Channel Strategy
20.4.26. Anixa Biosciences
20.4.26.1. Overview
20.4.26.2. Product Portfolio
20.4.26.3. Key Financials
20.4.26.4. SWOT Analysis
20.4.26.5. Key Developments
20.4.26.6. Sales Footprint
20.4.26.7. Strategy Overview
20.4.26.7.1. Marketing Strategy
20.4.26.7.2. Product Strategy
20.4.26.7.3. Channel Strategy
20.4.27. Ortho Clinical
20.4.27.1. Overview
20.4.27.2. Product Portfolio
20.4.27.3. Key Financials
20.4.27.4. SWOT Analysis
20.4.27.5. Key Developments
20.4.27.6. Sales Footprint
20.4.27.7. Strategy Overview
20.4.27.7.1. Marketing Strategy
20.4.27.7.2. Product Strategy
20.4.27.7.3. Channel Strategy
20.4.28. Fujirebio
20.4.28.1. Overview
20.4.28.2. Product Portfolio
20.4.28.3. Key Financials
20.4.28.4. SWOT Analysis
20.4.28.5. Key Developments
20.4.28.6. Sales Footprint
20.4.28.7. Strategy Overview
20.4.28.7.1. Marketing Strategy
20.4.28.7.2. Product Strategy
20.4.28.7.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Prostate-Specific Antigen Testing Market
